Last updated: June 22, 2026
Boehringer Ingelheim v. Sun Pharma (1:20-cv-01153) Litigation Summary and Patent/IP Analysis
Boehringer Ingelheim Pharmaceuticals Inc. (BIPI) v. Sun Pharmaceutical Industries Limited (Sun) in 1:20-cv-01153 is a U.S. federal Hatch-Waxman patent dispute framed around FDA approval and patent infringement theories tied to a generic entry. The case number indicates it was filed in 2020 and litigates Orange Book-listed patent rights asserted by BIPI against Sun’s ANDA-related market attempt.
No additional case metadata (court, active patents, asserted claims, procedural posture, settlement terms, or final merits outcome) is included in the input, so a complete litigation-specific infringement/validity analysis tied to particular patent numbers, deadlines, and outcomes cannot be produced.
What is the status of Boehringer Ingelheim Pharmaceuticals Inc. v. Sun Pharma 1:20-cv-01153?
Answer: Not determinable from the provided information.
Key status elements required for a status determination:
- Filing court and division (district)
- Case schedule (preliminary injunction, claim construction, summary judgment, trial date)
- Dismissal/settlement indicators
- Final judgment or pending posture
No such docket facts are present in the prompt, so status cannot be stated.
Which patents does Boehringer Ingelheim assert in 1:20-cv-01153?
Answer: Not determinable from the provided information.
A proper patent estate mapping requires at least one of:
- Specific Orange Book patent numbers
- Listed patents in the complaint caption/body
- Claim charts or asserted-claims references in motions/opinions
- Docket entries indicating the asserted patent list
The prompt does not include asserted patent identifiers.
What is the infringement theory in Boehringer Ingelheim v. Sun Pharma (1:20-cv-01153)?
Answer: Not determinable from the provided information.
A Hatch-Waxman infringement theory usually includes some combination of:
- Infringement by submission of an ANDA (35 U.S.C. § 271(e)(2))
- Infringement by manufacture, use, sale, offer for sale, or importation (post-approval activities)
- Induced/contributory infringement theories tied to specific dosage forms or labeling
Without drug identity, asserted claims, or patent numbers, the infringement theory cannot be stated accurately.
What defenses does Sun Pharmaceutical raise in 1:20-cv-01153?
Answer: Not determinable from the provided information.
Common generic-side defenses in these cases include:
- Non-infringement based on formulation/process/label differences
- Invalidity challenges (anticipation/obviousness, indefiniteness, written description/enablement, lack of utility where relevant)
- Statutory limitations (for example, damages limits depending on the procedural phase)
No defense content is provided.
Did the parties settle Boehringer Ingelheim v. Sun Pharma 1:20-cv-01153?
Answer: Not determinable from the provided information.
Settlement status typically appears in:
- Dismissal without prejudice or with prejudice
- Joint stipulation of dismissal
- Consent injunction language
- Court order reflecting private agreement
None is included in the prompt.
How do Paragraph IV and Orange Book listings factor into this dispute?
Answer: Not determinable from the provided information.
A full Paragraph IV/Orange Book analysis requires:
- The reference listed drug (RLD)
- The NDA/Orange Book patent list tied to the RLD
- Which patents were challenged (Paragraph IV vs. other certifications)
- Triggering statutory dates for 30-month stay relief and potential generic launch windows
The drug and Orange Book patent list are not provided.
What are the key litigation timelines for 1:20-cv-01153 (filing to resolution)?
Answer: Not determinable from the provided information.
A timeline requires docket dates, including:
- Complaint filing date (beyond year)
- Answer/Rule 12 motion dates
- Claim construction schedule
- Daubert and summary judgment milestones
- Hearing and disposition dates
No docket milestones are present.
Does the case involve biologics, biosimilars, or small-molecule ANDA exclusivity?
Answer: Not determinable from the provided information.
The case could involve:
- Small-molecule ANDA and Orange Book patents
- Biologics license application (BLA) and biosimilar pathways
- Different exclusivity regimes affecting timing and damages
The input does not identify the product type.
Which generic entry risks existed for Sun Pharma if BIPI prevailed?
Answer: Not determinable from the provided information.
A generic-entry risk assessment needs:
- The asserted patent types (composition, method-of-use, formulation, manufacturing)
- Likely launch date under 30-month stay schedule
- Whether an injunction was sought and whether it was granted
No such facts are provided.
How strong is the patent estate for BIPI in this case?
Answer: Not determinable from the provided information.
A strength assessment typically needs:
- Patent ages, remaining term, maintenance status
- Litigation history and PTAB activity (where relevant)
- Claim scope breadth and remaining claim term
- Prior art landscape
No patent data is provided.
How does this litigation compare with other Boehringer Ingelheim vs. generic challengers?
Answer: Not determinable from the provided information.
Comparative analysis requires:
- Other Boehringer generic suits with identifiable same product or same asserted patent family
- Outcomes and settlement patterns
- Common infringement theories and claim constructions
No comparative set is included.
What is the commercial exposure tied to this dispute for Sun and BIPI?
Answer: Not determinable from the provided information.
Commercial exposure depends on:
- Product revenue, channel mix, and generic share potential
- Exclusivity/patent expiry calendar and launch timing
- Injunction scope or settlement “at-risk” launch dates
Drug identity is missing.
Key Takeaways
- The case identifier 1:20-cv-01153 indicates a U.S. Hatch-Waxman-style dispute between Boehringer Ingelheim Pharmaceuticals Inc. and Sun Pharmaceutical Industries Limited, but the prompt provides insufficient information to map asserted patents, theories, defenses, procedural posture, or outcomes.
- A litigation summary that is accurate at the patent-number and timeline level cannot be generated from the single input line.
FAQs
- What court and judge heard Boehringer Ingelheim v. Sun 1:20-cv-01153?
- Which specific Orange Book patents were asserted in 1:20-cv-01153?
- What FDA submission (ANDA/BLA) and certification type drove the infringement claims?
- Did the case end in a dismissal, consent judgment, or trial verdict?
- What launch dates were impacted by the case’s automatic stay or injunction?
References
- No sources were provided in the prompt.
